Guadecitabine + Pembrolizumab
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Fallopian Tube Carcinoma
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Trial Timeline
Nov 11, 2016 → Mar 31, 2023
NCT ID
NCT02901899About Guadecitabine + Pembrolizumab
Guadecitabine + Pembrolizumab is a phase 2 stage product being developed by Merck for Recurrent Fallopian Tube Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02901899. Target conditions include Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Fallopian Tube Carcinoma were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02901899 | Phase 2 | Completed |
Competing Products
20 competing products in Recurrent Fallopian Tube Carcinoma